There is some pathetic drivel about things having changed since the consolidation in the entitlement offer. A subterfuge no doubt, and suspect this was somewhat planned all along with the consolidation. They prematurely announced the $10 mill from CellHeal in July 2023 and have clearly cocked that deal up ever since.
It was a always call option equivalent buy for me late in its price cycle (post 2023 raise) on the Chinese/Singapore deals that that they've clearly stalled on - no doubt their potential partners negotiating hard knowing their funding woes. This CEO doesn't have a clue on capital mkts and the Board should be strung up for dereliction of duty in not raising capital when the stock price was $4+ twice in 2022. How can they not get a decent $3 million loan/grant now on the back of Singpaore A*Star collaboration, or alleged pending Chinese partnerships defeats me.
I am taking a rib punch, but feel for long-term shareholders. This comedic Board and executive team have at last half yearly, raised $29,470,027 in capital since IPO from shareholders and had accumulated losses of $13,879,948 for a closing mkt cap of less than $4 million, after promising so much.
OSX Price at posting:
36.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)